209733-45-9 Usage
General Description
Anatibant is a synthetic peptide antagonist of the bradykinin B2 receptor, which is a validated target for the treatment of various inflammatory diseases. It has been shown to have potent anti-inflammatory and anti-nociceptive effects in preclinical studies, making it a promising candidate for the treatment of conditions such as acute pancreatitis, arthritis, and other inflammatory disorders. Anatibant works by blocking the binding of bradykinin to its receptor, thereby reducing the inflammatory response and associated pain. Clinical trials have shown some promising results, but further research is needed to fully evaluate its therapeutic potential.
Check Digit Verification of cas no
The CAS Registry Mumber 209733-45-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,9,7,3 and 3 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 209733-45:
(8*2)+(7*0)+(6*9)+(5*7)+(4*3)+(3*3)+(2*4)+(1*5)=139
139 % 10 = 9
So 209733-45-9 is a valid CAS Registry Number.
InChI:InChI=1/C34H36Cl2N6O5S/c1-20-18-21(2)41-31-24(20)6-3-8-28(31)47-19-25-26(35)13-14-29(30(25)36)48(45,46)42-17-4-7-27(42)34(44)40-16-5-15-39-33(43)23-11-9-22(10-12-23)32(37)38/h3,6,8-14,18,27H,4-5,7,15-17,19H2,1-2H3,(H3,37,38)(H,39,43)(H,40,44)
209733-45-9Relevant articles and documents
N-benzenesulfonyl-L-proline derivatives, method for preparing and therapeutic use
-
, (2008/06/13)
PCT No. PCT/FR97/02049 Sec. 371 Date May 6, 1999 Sec. 102(e) Date May 6, 1999 PCT Filed Nov. 14, 1997 PCT Pub. No. WO98/24783 PCT Pub. Date Jun. 11, 1998The present invention relates to compounds selected from the group consisting of (i) the compounds of formula I: in which: X is a halogen atom or a methyl group, A is a group -N(R3)CO- or -CO-N(R3)-, B is a single bond, -CH2- or -CH2-O-, R1 is H, a C1-C3 alkyl group or a CF3 group, R2 and R3 are each independently H or a C1-C3 alkyl group, W is CH or N, and n is 2, 3, 4 or 5; and (ii) their addition salts. It further relates to the process for their preparation and to their use in therapeutics, especially for combating pathological conditions involving bradykinin.
